MarketCap
Facebook
X
Telegram
Adamis Pharmaceuticals Corporation Income Statement 2022-2010 | ADMP
Brief overview of revenue and earnings at Adamis Pharmaceuticals Corporation
This overview is based on financial performance over the past five years. Revenue at Adamis Pharmaceuticals Corporation moved from 13.1 million dollars in 2017 to 4.8 million dollars in 2022. The five-year change reached −63.6%, while CAGR stood at −18.3%. Revenue ended the period on a sustained downward trend.
The five-year change in gross profit reached −125.3%: from 5.7 million dollars to −1.4 million dollars. The relationship between sales and direct costs deteriorated. At the margin level, the figure shifted from 43.2% to −30.1%. The business retained less gross profit from each unit of revenue.
The operating result measured by EBITDA moved from −$21.7 million to −$23.6 million, or −8.5%. EBITDA grew faster than revenue, indicating positive operating leverage. EBITDA margin was −166.2% at the start and −495.7% at the end. The margin contraction indicates weaker operating efficiency.
Net income moved from −$25.5 million at the start to −$26.5 million at the end. The negative result deepened, showing weaker final efficiency.
Market capitalization changed from $103 million to $18 million (−82.6%). Capitalization grew more slowly than the underlying results.
Summary assessment
The results contain several connected negative signals. The constructive conclusion rests on consistent net profitability. The main areas of concern are a low EBITDA margin, weaker operating efficiency and weak sales momentum. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
18 M | 86.5 M | 89.2 M | 35.2 M | 120 M | 103 M | 54.3 M | 63.1 M | 71.8 M | 39 M | 1.03 B | 184 M | - |
Shares |
150 M | 144 M | 77.6 M | 53.3 M | 39.1 M | 28.3 M | 17.5 M | 13.3 M | 10.5 M | 5.86 M | 89.5 M | 63.8 M | - |
Historical Prices |
0.12 | 0.6 | 1.15 | 0.66 | 3.07 | 3.65 | 3.1 | 4.75 | 6.82 | 6.66 | 11.6 | 2.89 | - |
Net Income |
-26.5 M | -45.8 M | -49.4 M | -27.5 M | -39 M | -25.5 M | -19.4 M | -13.6 M | -9.32 M | -6.6 M | -4.92 M | -6.98 M | - |
Revenue |
4.76 M | 2.21 M | 2.78 M | 22.1 M | 15.1 M | 13.1 M | 6.47 M | - | - | - | - | - | - |
Cost of Revenue |
6.19 M | 6.87 M | 6.33 M | 15.5 M | 9.8 M | 7.42 M | - | - | - | - | - | - | - |
Gross Profit |
-1.43 M | -4.66 M | -3.55 M | 6.64 M | 5.29 M | 5.65 M | 1.62 M | - | - | - | - | - | - |
Operating Income |
-25.1 M | -32.1 M | -36.3 M | -29.4 M | -39.5 M | -24.8 M | -25.2 M | -13.9 M | -8.1 M | -2.68 M | -4.82 M | -6.24 M | - |
Interest Expense |
- | 6.65 K | 4.92 K | 123 K | 158 K | 231 K | 214 K | - | 226 K | 8.48 M | 35.4 K | 744 K | - |
EBITDA |
-23.6 M | -30.6 M | -34 M | -26.4 M | -36.4 M | -21.7 M | -22.7 M | -12.9 M | -7.21 M | -2.68 M | -4.82 M | -6.23 M | - |
Operating Expenses |
- | - | 38.9 M | 35.7 M | 44.7 M | 30.3 M | 26.8 M | 13.9 M | 4.4 M | 3.22 M | 4.82 M | 6 M | - |
General and Administrative Expenses |
13.2 M | 16.1 M | 20.1 M | 25.3 M | 25.9 M | 22.8 M | 17.1 M | 9.01 M | 4.56 M | 2.05 M | 2.65 M | 3.37 M | - |
All numbers in USD currency
Quarterly Income Statement Adamis Pharmaceuticals Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
7.07 M | 2.57 M | 153 M | 2.14 M | 150 M | 150 M | 150 M | 150 M | 149 M | 149 M | 129 M | 93.8 M | 76 M | 73.8 M | 66.5 M | 61.8 M | 56.3 M | 47.5 M | 47.3 M | 47.3 M | 42.1 M | 33.4 M | 33.4 M | 33.4 M | 31.5 M | 26.2 M | 22.1 M | 22 M | 19.6 M | 15.4 M | 13.4 M | 13.4 M | 13.4 M | 13.4 M | 12.8 M | 10.7 M | 10.5 M | 10.7 M | 10.5 M | 6.74 M | 6.74 M | 105 M | 104 M | 5.81 M | 98.8 M | 98.3 M | 97.2 M | 91.9 M | 93.1 M | 90.3 M | 87.9 M |
Net Income |
-1.39 M | -8.57 M | -8.94 M | - | -4.4 M | -8.4 M | -10.4 M | - | -12.4 M | -9.31 M | -15.4 M | - | -7.49 M | -11.3 M | -10.3 M | - | -7 M | -7.74 M | -8.89 M | - | -8.88 M | -9.7 M | -7.62 M | - | -6.77 M | -4.97 M | -5.77 M | - | -6.64 M | -5.71 M | -6.41 M | - | -3.15 M | -3.64 M | -3.14 M | - | -2.12 M | -2.12 M | -2.88 M | -5.53 M | -5.53 M | -32 K | -1.04 M | -1.97 M | -1.97 M | -857 K | -2.73 M | -991 K | -991 K | -2.71 M | -1.24 M |
Revenue |
9.06 K | 6.94 K | 1.45 M | - | 1.51 M | 39.8 K | 1.15 M | - | 760 K | 4.01 M | 4.11 M | - | 4.3 M | 3.93 M | 4.66 M | - | 5.9 M | 5.76 M | 4.91 M | - | 3.83 M | 3.92 M | 3.18 M | - | 3.39 M | 3.81 M | 3.04 M | - | 2.08 M | 1.93 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
338 K | 361 K | 1.79 M | - | 1.65 M | 689 K | 1.46 M | - | 1.24 M | 3.87 M | 3.64 M | - | 3.65 M | 4.68 M | 3.69 M | - | 3.99 M | 3.67 M | 3.63 M | - | 2.3 M | 2.39 M | 2.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
-329 K | -354 K | -335 K | - | -142 K | -649 K | -309 K | - | -476 K | 141 K | 467 K | - | 654 K | -757 K | 976 K | - | 1.91 M | 2.1 M | 1.28 M | - | 1.53 M | 1.53 M | 1.12 M | - | 1.3 M | 1.92 M | 1.37 M | - | 255 K | 582 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-3.27 M | -11.3 M | -6.43 M | - | -4.63 M | -8.18 M | -7.91 M | - | -10.2 M | -9.23 M | -7.71 M | - | -6.84 M | -11.2 M | -10.3 M | - | -7.01 M | -7.75 M | -8.94 M | - | -8.91 M | -9.67 M | -7.61 M | - | -5.8 M | -4.92 M | -5.71 M | - | -6.58 M | -7.43 M | -6.02 M | - | -3.31 M | -3.53 M | -4.15 M | - | -1.94 M | -1.94 M | -2.75 M | -984 K | -984 K | -957 K | -740 K | -748 K | -748 K | -851 K | -725 K | -989 K | -989 K | -1.47 M | -1.21 M |
Interest Expense |
29.5 K | 46.3 K | -113 K | - | 1.86 K | 2.9 K | 1.88 K | - | 1.86 K | 44.9 K | 39.3 K | - | 46 K | 32.9 K | 38.3 K | - | 21.9 K | 23 K | 24 K | - | 30.7 K | 51.4 K | 50.7 K | - | 52.6 K | 59.4 K | 67.5 K | - | 70.2 K | 72.4 K | - | - | 371 K | 226 K | 145 K | - | 371 K | 226 K | 226 K | 5.3 M | 5.3 M | 2.78 M | 405 K | 845 K | 845 K | 579 K | 295 K | 2.61 K | 2.61 K | 2.55 K | 27.5 K |
EBITDA |
-3 M | -11.1 M | -6.32 M | - | -4.23 M | -7.81 M | -7.57 M | - | -9.15 M | -8.55 M | -7.07 M | - | -5.94 M | -10.4 M | -9.34 M | - | -4.91 M | -6.29 M | -8.15 M | - | -6.59 M | -8.13 M | -6.84 M | - | -3.48 M | -3.36 M | -4.93 M | - | -4.82 M | -7.28 M | -5.77 M | - | -2.56 M | -3.04 M | -3.91 M | - | -1.05 M | -1.35 M | -2.45 M | -984 K | -984 K | -957 K | -740 K | -748 K | -748 K | -851 K | -725 K | -989 K | -975 K | -1.46 M | -1.21 M |
General and Administrative Expenses |
2.52 M | 4.03 M | 4.78 M | - | 2.51 M | 4.21 M | 3.38 M | - | 4.79 M | 7.13 M | 5.92 M | - | 5.79 M | 5.65 M | 6.05 M | - | 5.3 M | 7 M | 8.02 M | - | 6.53 M | 6.36 M | 6.47 M | - | 5.75 M | 5.66 M | 5.57 M | - | 5.34 M | 4.58 M | 2.62 M | - | 2.13 M | 2.26 M | 2.79 M | - | 1.34 M | 1.34 M | 1.01 M | 776 K | 776 K | 762 K | 515 K | 542 K | 542 K | 430 K | 617 K | 807 K | 807 K | 895 K | 582 K |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Adamis Pharmaceuticals Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Irlanda
Canada
Schweden
China
France
